Report of University Hospital Hradec Králové to the clinical trial protocol No: GS-US-352-0101

Abstract

Realization of part of clinical trial called: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Keywords

• Momelotinib
• Ruxolitinib
• Primary Myelofibrosis